Biomet Stockholders Urged to Reject Buyout

An independent proxy company is recommending that Biomet shareholders reject a 10-point-nine billion dollar purchase offer. In December, a group of private investors offered $44 per share for the Warsaw orthopedics company, but the proxy company says Biomet’s value has increased since then.